Back to Search Start Over

GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery

GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery

Authors :
Universidad de Sevilla. Departamento de Química Orgánica y Farmacéutica
Carullo, Gabriele
Mazzotta, Sarah
Vega Holm, Margarita
Iglesias Guerra, Fernando
Vega Pérez, José Manuel
Aiello, Francesca
Brizzi, Antonella
Universidad de Sevilla. Departamento de Química Orgánica y Farmacéutica
Carullo, Gabriele
Mazzotta, Sarah
Vega Holm, Margarita
Iglesias Guerra, Fernando
Vega Pérez, José Manuel
Aiello, Francesca
Brizzi, Antonella
Publication Year :
2021

Abstract

The G-protein coupled receptors (GPCRs) activated by free fatty acids (FFAs) have emerged as new and exciting drug targets, due to their plausible translation from pharmacology to medicines. This perspective aims to report recent research about GPR120/FFAR4 and its involvement in several diseases, including cancer, inflammatory conditions, and central nervous system disorders. The focus is to highlight the importance of GPR120 in Type 2 diabetes mellitus (T2DM). GPR120 agonists, useful in T2DM drug discovery, have been widely explored from a structure–activity relationship point of view. Since the identification of the first reported synthetic agonist TUG-891, the research has paved the way for the development of TUG-based molecules as well as new and different chemical entities. These molecules might represent the starting point for the future discovery of GPR120 agonists as antidiabetic drugs.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1367052174
Document Type :
Electronic Resource